The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

On Tap at SITC 2017 - Nov. 10


On Tap Today

The wait is over! The 32nd Annual Meeting (SITC 2017) kicks off this morning. On-site registration and badge pickup opens at 7 a.m. for those who are joining us for the first time this week, with a breakfast also available before sessions begin at 8 a.m.

SITC 2017 is the first Annual Meeting for Lisa H. Butterfield, PhD, as President of the society. Dr. Butterfield had served as Vice President of SITC the past two years before becoming the first female President of SITC in its history following last year's Annual Meeting.


32nd Annual Meeting & Pre-Conference Programs

32nd Annual Meeting - Friday Programming

8 a.m. - 6:35 p.m. / Maryland & Cherry Blossom Ballrooms

The day's programming opens with the National Cancer Institute update from T. Kevin Howcroft, PhD and Julius Strauss, MD, the latter of whom will discuss his 2016 NCI Immunotherapy Fellowship.

Stephan Grupp, MD, PhD
One of the day's highlights will be the day's keynote speech from Stephen Grupp, MD, PhD of the Children's Hospital of Philadelphia. Dr. Grupp will deliver his presentation on "The CAR T Revolution in Leukemia." On Aug. 30, 2017, the U.S. Food and Drug Administration (FDA) granted historic approval of chimeric antigen receptor T cell (CAR T) therapy for use in pediatric and young adult patients with a form of acute lymphoblastic leukemia. Based on Dr. Grupp's experience treating patients with high-risk pediatric cancers, he will present results from the clinical trial of CAR T therapy that led to this initial FDA approval, which is rapidly altering the field of oncology.

Today's late-breaking abstract session from Noon - 12:30 p.m. in the Maryland Ballroom features the following presentations:
  • Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies  
    • Thomas S. Uldrick, MD, MD – National Cancer Institute
  • Nivolumab in Mismatch-Repair Deficient (MMR-d) Cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D Preliminary Results 
    • Nilofer Azad, MD – Johns Hopkins University
Poster viewing will take place over lunch from 12:30 - 2 p.m. in the Prince George Exhibition Hall DE, before again in the evening from 6:45 - 8 p.m.

Organizers for the 32nd Annual Meeting are:
  • Charles G. Drake, MD, PhD – Columbia University Medical Center 
  • Susan M. Kaech, PhD – Yale University 
  • Marcela V. Maus, MD, PhD – Massachusetts General Hospital Cancer Center 
  • Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Members of the Annual Program Oversight Committee are:
  • Chair: Mario Sznol, MD – Yale School of Medicine 
  • Charlie Garnett Benson, PhD – Georgia State University 
  • Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
 Click here to view the full program schedule

Continuing Education Information

This is your friendly reminder that you can earn continuing education credit while at SITC 2017!

Jointly provided by the Postgraduate Institute for Medicine and SITC, credits are available to physicians, nurses and pharmacists.

Click here to learn more about how to obtain your credit(s.

Presidential Reception & Membership Business Meeting

8 - 9 p.m. / Cherry Blossom Ballroom

Lisa H. Butterfield, PhD - SITC President
Join your fellow colleagues and meeting attendees for the State of SITC: Membership Business Meeting, featuring updates on the current activities of the society, the year in review and highlights of exciting initiatives moving forward. Immediately following, join other attendees for the Presidential Reception, the official kickoff event of the 32nd Annual Meeting.

No comments:

Post a Comment